Lupeng Pharmaceutical Ventures into Hong Kong Stock Exchange: Can Antimicrobial Resistance Inhibitors Shape an 18A New Tale?

Lupeng Pharmaceutical, a Guangzhou-based company, is making its second attempt at a mainboard IPO on the Hong Kong Stock Exchange. The company’s key asset, LP-168, a “covalent + non-covalent” dual mechanism BTK inhibitor, has entered the NDA stage in China, becoming the first of its kind in the country. Lupeng’s IPO timeline shows a previous submission in October 2025 that automatically lapsed after a 6-month non-auditory period, followed by a second IPO application on May 28, 2026. Lupeng aims to become another Guangzhou-based Biotech company to debut on the Hong Kong Stock Exchange as an unprofitable biotech entity (18A).